Search
forLearn
5 / 801 resultslearn ORPL
learn nicotinamide
learn NMN
learn Ceramide NP
Research
5 / 1000+ results
research Revised NPRT Classification System Encompasses Additional Patterns of Male and Female Hair Loss
The updated NPRT system now covers different types of hair loss in men and women.
research Evaluation of Five Hundred Patients using Ahmad’s NPRT System for Documenting Male Pattern Baldness
Ahmad's NPRT system accurately documents and predicts male pattern baldness.
research How I Do It: Ahmad’s NPRT System: A New Classification System for Documenting Male Pattern Baldness
Dr. Muhammad Ahmad created a simpler system to better describe male pattern hair loss.
research Determination of Vitamin B3 Vitamer (Nicotinamide) and Vitamin B6 Vitamers in Human Hair Using LC-MS/MS
The method can measure vitamin B3 levels in human hair accurately.
research Clinical experience on follicular unit extraction megasession for severe androgenetic alopecia
FUE megasession effectively treats severe hair loss with natural-looking results in one operation.
Community Join
5 / 1000+ resultscommunity Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community Proof DHT is not the main cause of hair loss. TRPS1 Gene and Protein might be. PP405 won’t work. AMP-303 might!
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.
community Trestolone (MENT) as a nuclear treatment
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.